AR080884A1 - INSULIN-SIRNA CONJUGATES - Google Patents

INSULIN-SIRNA CONJUGATES

Info

Publication number
AR080884A1
AR080884A1 ARP110101227A ARP110101227A AR080884A1 AR 080884 A1 AR080884 A1 AR 080884A1 AR P110101227 A ARP110101227 A AR P110101227A AR P110101227 A ARP110101227 A AR P110101227A AR 080884 A1 AR080884 A1 AR 080884A1
Authority
AR
Argentina
Prior art keywords
refers
insulin
specifically
methods
metabolic diseases
Prior art date
Application number
ARP110101227A
Other languages
Spanish (es)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR080884A1 publication Critical patent/AR080884A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere de forma general a compuestos terapéuticos y métodos utiles para tratar a enfermedades en seres humanos. Más concretamente, se refiere a métodos y reactivos utiles para tratar a seres humanos que padecen enfermedades metabolicas. Más concretamente, se refiere a conjugados covalentes de insulina y análogos con derivados de ácidos nucleicos que son capaces de modular la expresion de genes. Además, esta se refiere al uso de dichas insulinas conjugadas para el tratamiento de enfermedades metabolicas, incluyendo la diabetes mellitus. Reivindicacion 1: El compuesto quimérico que comprende una insulina y su siRNA.It refers generally to therapeutic compounds and useful methods for treating diseases in humans. More specifically, it refers to methods and reagents useful for treating humans suffering from metabolic diseases. More specifically, it refers to covalent insulin conjugates and analogs with nucleic acid derivatives that are capable of modulating gene expression. In addition, this refers to the use of said conjugated insulins for the treatment of metabolic diseases, including diabetes mellitus. Claim 1: The chimeric compound comprising an insulin and its siRNA.

ARP110101227A 2010-04-14 2011-04-12 INSULIN-SIRNA CONJUGATES AR080884A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305388 2010-04-14

Publications (1)

Publication Number Publication Date
AR080884A1 true AR080884A1 (en) 2012-05-16

Family

ID=42633135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101227A AR080884A1 (en) 2010-04-14 2011-04-12 INSULIN-SIRNA CONJUGATES

Country Status (4)

Country Link
AR (1) AR080884A1 (en)
TW (1) TW201141513A (en)
UY (1) UY33326A (en)
WO (1) WO2011128374A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56632B1 (en) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
PT3345593T (en) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
ES2855146T3 (en) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (en) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
MX369511B (en) 2013-04-03 2019-11-11 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins.
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (en) 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE10075034I1 (en) 1987-02-25 2001-05-23 Novo Nordisk As Insulin derivatives
RO112873B1 (en) 1993-09-17 1998-01-30 Novo Nordisk As Insulin derivatives
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US20060019913A1 (en) 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
AU2003283951A1 (en) 2002-05-23 2004-03-03 Ceptyr, Inc. Modulation of biological signal transduction by rna interference
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
JP5624256B2 (en) * 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド Delivery of therapeutic compounds to the brain and other tissues
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
JP4818361B2 (en) 2005-07-08 2011-11-16 バイオコン・リミテッド Preparation of insulin conjugate
US8058391B2 (en) 2005-10-13 2011-11-15 Biocon Limited Process for the preparation of insulin conjugate IN-105
CA2628113A1 (en) 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
EP2131855A2 (en) 2007-03-05 2009-12-16 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery

Also Published As

Publication number Publication date
UY33326A (en) 2011-12-01
WO2011128374A1 (en) 2011-10-20
TW201141513A (en) 2011-12-01

Similar Documents

Publication Publication Date Title
AR080884A1 (en) INSULIN-SIRNA CONJUGATES
CY1120685T1 (en) RETINOID-LIPOSOMES TO STRENGTHEN HSP47 EXPRESSION REGULATION
CY1119582T1 (en) HYDRAULIC INSULIN PREPARATIONS CONTAINING Methionine
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
UY31596A1 (en) NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / ACTION PROFILE
NZ595189A (en) Combination therapy with thiocolchicine derivatives
CL2013000020A1 (en) Method for controlling a pest of coleoptero insects which comprises supplying a pest of coleopteros or its surroundings with a composition containing at least one active protein against catheters, such as the modified cry3a protein active against lepidoptera, such as the cry1ab protein
BR112013027119A8 (en) new ligand-drug conjugates (adcs) and their use
WO2010036918A3 (en) Intracellular dna receptor
AR083715A1 (en) COMPOSITIONS AND METHODS FOR THE SELECTIVE DISTRIBUTION OF MOLECULES OF OLIGONUCLEOTIDES TO SPECIFIC TYPES OF NEURONES
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CL2011000899A1 (en) Aryl compounds, modulators of gpr120 activity in a cell; pharmaceutical composition; and use of said compounds for the treatment of type i, ii diabetes, metabolic syndrome, stimulate insulin production, lower blood glucose level.
CO6650337A2 (en) Novel 3-hydroxy-5-arylisothiazole derivatives
NI201100082A (en) ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER.
AR086272A2 (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
EA032867B9 (en) Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
CL2012000248A1 (en) Insulin conjugated compound; preparation procedure; pharmaceutical composition comprising it; pharmaceutical combination; pharmaceutical kit; use in the treatment of insulin-mediated disorders.
NZ595891A (en) Modulation of inflammatory responses by factor xi
MX366314B (en) Treating diabetes melitus using insulin injections administered with varying injection intervals.
AR082312A1 (en) A PHARMACEUTICAL COMBINATION COMPOSITION TO TREAT DIABETES AND METABOLIC DISORDERS
NI201200134A (en) AGONIST POLYPEPTIDES THAT BIND TO DR5
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
CL2009001240A1 (en) Compounds derived from l-glutamic acid and l-glutamine labeled with [f-18]; preparation procedure; pharmaceutical composition comprising the compounds and their use as agents in the diagnosis of tumors.
BR112012014760A2 (en) "organic compositions for treating hsf1-related diseases and their use"

Legal Events

Date Code Title Description
FB Suspension of granting procedure